Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Achilles Therapeutics

Evaluate

Thumbnail
October 14, 2022

Cancer “vaccines” enter the neoantigen stage

Attempts to raise a personalised immune response against neoantigens have attracted big pharma interest, most recently from Merck & Co.

Thumbnail
September 29, 2021

Crucial clinical events for the smaller players

Data are due in the fourth quarter for Aldeyra, Aeglea and Radius, among other small developers.

Article image
Vantage logo
May 26, 2021

Vectura marks a sorry outcome for UK biotech

Article image
Vantage logo
May 19, 2021

Iovance delayed again

Article image
Vantage logo
October 06, 2020

Iovance delayed TIL when?

Article image
Vantage logo
April 27, 2020

AACR 2020 – Iovance doesn’t disappoint

Article image
Vantage logo
February 26, 2020

Iovance bulls should focus on execution

The cell therapy player, aiming to take TILs out of academia into a commercial setting, has surged on unsubstantiated takeover rumours.

Article image
Vantage logo
October 07, 2019

Venture cash gets even more concentrated

The latest venture capital numbers suggest that 2019 will see a healthy amount raised, but the falling number of rounds could be a worry.

Article image
Vantage logo
September 03, 2019

No heel needed for Achilles

Article image
Vantage logo
June 27, 2019

Bracco’s Blue Earth buy boosts Syncona

Syncona might have hoped for a bigger payday with the prostate imaging specialist, but it has plenty more irons in the fire.

Vantage logo
October 24, 2017

Interview – Syncona’s uncompromising message to the European markets

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up